Hasholzner U, Stieber P, Reiter W, Zimmermann A, Hofmann K, Schalhorn A
Institute of Clinical Chemistry, University of Munich, FRG.
Anticancer Res. 1999 Jul-Aug;19(4A):2477-80.
In a prospective study (N = 566) we investigated the tumour associated carbohydrate-protein CA 242, focusing on the question whether CA 242 (CaNAG, Sweden) expression in carcinoma patients is distinctly higher than in benign disorders, especially when compared to CA 19-9 (EIA Roche Germany). A second point of interest was if CA 242 is expressed to a higher extent in early stages of colorectal cancer than CEA (MEIA Abbott, USA) and CA 19-9 are, and third its behavior in pancreatic and lung cancer. We found CA 242 values comparable in healthy individuals and benign gastrointestinal disorders, thus CA 19-9 remains the marker of first choice for pancreatic cancer and CEA for colorectal cancer. CA 242 shows no advantage in lung cancer as compared to the established markers (CEA, CYFRA 21-1 (EIA Roche Germany) and NSE (EIA Hoffmann LaRoche, Switzerland) and no clearly higher expression in early colorectal cancer. Overall, the combination of CEA and CA 242 shows the best sensitivity in colorectal cancer.
在一项前瞻性研究（N = 566）中，我们对肿瘤相关糖蛋白CA 242进行了研究，重点关注癌患者中CA 242（瑞典CaNAG）的表达是否明显高于良性疾病，特别是与CA 19-9（德国罗氏酶免疫分析）相比时。另一个关注点是，在结直肠癌早期，CA 242的表达程度是否高于癌胚抗原（美国雅培微粒子酶免疫分析）和CA 19-9，以及其三是其在胰腺癌和肺癌中的表现。我们发现健康个体和良性胃肠道疾病患者的CA 242值相当，因此CA 19-9仍然是胰腺癌的首选标志物，癌胚抗原是结直肠癌的首选标志物。与既定标志物（癌胚抗原、细胞角蛋白19片段（德国罗氏酶免疫分析）和神经元特异性烯醇化酶（瑞士罗氏诊断酶免疫分析）相比，CA 242在肺癌中没有优势，在结直肠癌早期也没有明显更高的表达。总体而言，癌胚抗原和CA 242联合检测在结直肠癌中显示出最佳敏感性。
